Global Invasive Fungal Infection (IFI) Market Report 2020 - Surging Demand for Low-Cost Pipeline Products, Increase in Use of Broad-Spectrum Antibiotics
DUBLIN, Feb. 3, 2020 /PRNewswire/ -- The "Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The Global Invasive Fungal Infection Market was valued at USD 6,103.5 Million in the year 2018.
The rise in population suffering from HIV/AIDS, discovery and advancement of pipeline drugs and facilities provided by hospitals in intensive care units for those who have undergone surgery, surge in chemotherapy and increase in use of broad spectrum antibiotics and global economic growth is going to accelerate the invasive fungal infection market. Introduction of advanced medicines has already proven to be constructive as it directly improves the health of immuno-compromised patient and enhances the life expectancy of a patient.
The Invasive Fungal Infection market has been estimated to witness growth in future primarily because of surging demand for low-cost pipeline products and increase in use of broad-spectrum antibiotics which makes fungi resistant to various medicines and to opt for the low-cost medicines whose effect can last longer than the traditional medicines.
A number of companies are offering variety of antibiotics which have decreased the resistance of several medicines, thus increasing the incidence of invasive fungal infection. In addition, rising investment by major leading Invasive Antifungal manufacturers in various regions with demand for effective and low cost product and focus of government on educating people about the care taken during the stay in ICU after undergoing solid organ transplantation with various government powered awareness programs that are being run with an aim to eradicate diseases, has been anticipated to spur the market growth during the forecast period.
Scope of the Report
-- There report analyzes the Global Invasive Fungal Infection Market By
Diseases (Candidemia and invasive Candidiasis, Intra-abdominal
candidiasis (Candida Peritonitis), Cryptococcal Meningitis,
Histoplasmosis Disseminated, Histoplasmosis Acute Pulmonary, Invasive
aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis
Pneumonia, Others).
-- The Global Invasive Fungal Infection Market has been analysed By Region
(North America, Europe, Asia Pacific, ROW) and By Country (United
States, Canada, Germany, France, United Kingdom, Spain, China, South
Korea, Japan, India).
-- The key insights of the report have been presented through the
frameworks of SWOT, Porter and Market Attractiveness charts. Market
Attractiveness charts have been presented by diseases and by region.
Additionally, the major opportunities, trends, drivers and challenges of
the industry has been analysed in the report.
-- The report provides a detailed pipeline analysis of drugs being
developed to cure the problem of Invasive Fungal Infection.
-- The report tracks competitive developments,market share analysis,
strategies and new product development. The companies analysed in the
report include Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline,
Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G - The Rare
Fungal Disease Company, Scynexis Inc
-- The report presents the analysis of Global Invasive Fungal Infection
Market for the historical period of 2014-2018 and the forecast period of
2019-2024.
Key Topics Covered
1. Report Scope & Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
2.1 Both Healthcare Providers and Public Health Agencies to Improve Diagnostics
2.2 Escalate the Awareness Among the Population of APAC Region
3. Global Invasive Fungal Infection Product Outlook
4. Global Invasive Fungal Infection Market: Sizing, Growth, Forecast
4.1 Market Size, By Value, Year 2014-2024
5. Global Invasive Fungal Infection Market Segmentation By Diseases
5.1 Competitive Scenario of Global Invasive Fungal Infection Market: By Diseases
5.2 Candidaemia and Invasive Candiasis - Market Size and Forecast (2019-2024)
5.3 Intra-abdominal Candiasis (Candida Peritonitis) - Market Size and Forecast (2019-2024)
5.4 Cryptococcal Meningitis - Market Size and Forecast (2019-2024)
5.5 Histoplasmosis Disseminated - Market Size and Forecast (2019-2024)
5.6 Histoplasmosis Acute Pulmonary - Market Size and Forecast (2019-2024)
5.7 Invasive Aspergillosis - Market Size and Forecast (2019-2024)
5.8 Invasive Rhinosinusitis - Market Size and Forecast (2019-2024)
5.9 Mucormycosis - Market Size and Forecast (2019-2024)
5.10 Pneumocystis Pneumonia - Market Size and Forecast (2019-2024)
5.11 Others - Market Size and Forecast (2019-2024)
6. Global Invasive Fungal Infection Market: Regional Analysis
6.1 Competitive Scenario of Global Invasive Fungal Infection: By Region
7. North America Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)
8. Europe Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)
9. Asia-Pacific Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)
10. Rest of the World Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024)
11. Global Invasive Fungal Infection Market Dynamics
11.1 Global Invasive Fungal Infection Market Drivers
11.2 Global Invasive Fungal Infection Market Restraints
11.3 Global Invasive Fungal Infection Market Trends
12. Pipeline Drugs Analysis - Invasive Fungal Infection
13. Market Attractiveness and Strategic Analysis
13.1.1 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases (Year 2024)
13.1.2 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region (Year 2024)
14. Competitive Landscape
14.1 Market Share Analysis
14.2 SWOT Analysis
14.3 Porter's Five Force Analysis
15. Company Analysis (Business Description, Financial Analysis, Business Strategy)
15.1 Cidara Therapeutics
15.2 Basilea Pharmaceutica
15.3 Pfizer
15.4 GlaxoSmithKline
15.5 Bayer AG
15.6 Abbott
15.7 Merck & Co
15.8 Astellas Pharma Inc.
15.9 F2G - the Rare Fungal Disease Company
15.10 Scynexis Inc.
For more information about this report visit https://www.researchandmarkets.com/r/gaw4f8
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
